Home > Investor Relations > Financial Results > Latest Results

Latest Results

July 26, 2018

FY2018 2Q Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
285,123 (129,068) (33,195) (48,533) (7,757)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
66,569 23.3 64,996 49,047 89.00

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
873,347 250,423 622,924 (21,877) (119,811)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
731,174 14.5 83.7 62.00 (Forecast) 31.00

Revenues: 285.1 billion JPY (+32.3, +12.8% YoY)

Domestic sales excl. Tamiflu®: slight decrease due to impact from HIP revision, although sales of mainstay products continued to grow (-0.3, -0.2%)
Overseas sales: growth of Actemra® export to Roche, etc. (+18.8, +41.1%)
Royalties and other operating income: one-time income from transfer of long-listed products on HIP list, etc. (+13.6, +85.5%)

Cost of sales / Operating expenses (Core basis)

Cost of sales: the ratio to sales improved due to a change in product sales mix, etc. (-0.7% points, from 51.0% to 50.3%)
Operating expenses: overall increase mainly due to the increase of research and development expenses (-3.1, +3.8%)

Profits

IFRS results:  
operating profit  66.6 billion JPY (+19.5, +41.4%)
net income  49.0 billion JPY (+12.5, +34.2%)
Core results:  
operating profit  71.6 billion JPY (+21.4, +42.6%)
net income  52.6 billion JPY (+13.8, +35.6%)
EPS  95.27 JPY (+25.17, +35.9%)

Jan-Jun 2018 Sales excluding Tamiflu®

Core Operating Income Jan-Jun

*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.

To view PDF files,
you will need Adobe® Reader® which is available as a free download.